UICC

La Roche-Posay Continues its 25-year Commitment to Holistic Supportive Care for Cancer Patients Worldwide

Retrieved on: 
Tuesday, October 31, 2023
Family, Union, UICC, Learning, Woman, Union for International Cancer Control, Cancer, Caregiver, Education, Patient, Partnership, La Roche-Posay, Friends, Nursing

NEW YORK, Oct. 31, 2023 /PRNewswire/ -- ⅕ of men and ⅙ of women will face cancer during their lifetime1, meaning that everyone everywhere will be touched by its impact, either directly or through friends, family and loved ones. La Roche-Posay, the leader in pioneering life-changing skincare powered by innovation and education for all, has been committed to helping cancer patients through oncology initiatives for more than 25 years.

Key Points: 
  • La Roche-Posay, the leader in pioneering life-changing skincare powered by innovation and education for all, has been committed to helping cancer patients through oncology initiatives for more than 25 years.
  • This year, in partnership with the Union for International Cancer Control (UICC), La Roche-Posay is proud to raise even more awareness and have an even greater impact within its "Healing Power of Touch'' campaign with the launch of its first digital learning platform, cancer-support.com .
  • This learning portal empowers cancer patients and caregivers with the training they need to improve lives, starting from just 15 minutes of education.
  • 80% of patients confirm that supportive care has helped them in their management of their diagnosis2, making training essential.

Venatorx Announces Presentation of Analysis of Cefepime-Taniborbactam in vitro Activity against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer at IDWeek 2023

Retrieved on: 
Monday, October 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, PWC, Infection, Incidence, CRE, Gram-negative bacteria, Extended-spectrum penicillin, Bacteria, GN, Risk, Escherichia coli, UICC, Enterobacterales, Ceftolozane/tazobactam, Cancer, MD Anderson Cancer Center, Pseudomonas aeruginosa, MDR, University, Ceftazidime/avibactam, Medication, ESBL, Serine, Patient, AMR, Pharmaceutical industry

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.

Key Points: 
  • Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with drug-resistant bacterial infections and hard-to-treat viral infections, today announces the presentation of data during IDWeek 2023 , October 11-15, 2023, in Boston, MA on the in vitro activity of cefepime-taniborbactam, an investigational antibacterial agent, in comparison to other antibiotics against clinically significant gram-negative bacteria isolated from patients with cancer.
  • The bacterial isolates tested included Extended Spectrum β-lactamase (ESBL) producing Enterobacterales and Carbapenem Resistant Enterobacterales (CRE) isolates, and MDR Pseudomonas aeruginosa.
  • In the study, cefepime-taniborbactam demonstrated higher in vitro activity than the tested comparators.
  • While cefepime-taniborbactam has not yet been approved for clinical use, only 3 of the 270 isolates (1.1%; 2 CRE Escherichia coli and 1 MDR P. aeruginosa) were found to be resistant to cefepime-taniborbactam at its provisional breakpoint.

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Retrieved on: 
Thursday, September 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Philanthropy, Foundation, Partnership, Senior, OR, Jim Valvano, Cancer, Bristol Myers Squibb, Multimedia, Country, Dollar for Dollar, BMY, Organization, CNJ, Union for International Cancer Control, Patient, Union, UICC, NYSE, Disease, Jersey Shore, Pharmaceutical industry, Amusement park, Immunology

Since its inception in 2014, Bristol Myers Squibb employees – who have all been personally impacted by cancer – have come together to raise more than $11.3 million for cancer research in the United States.

Key Points: 
  • Since its inception in 2014, Bristol Myers Squibb employees – who have all been personally impacted by cancer – have come together to raise more than $11.3 million for cancer research in the United States.
  • The ride has since expanded to Europe, Japan and Latin America where employees raise funds for international cancer organizations.
  • I’m equally proud to work for a company that is so committed to making a difference.”
    Funds donated to the V Foundation support innovative cancer research at prominent cancer centers nationwide.
  • For more information, or to support the riders in the 2023 Coast 2 Coast 4 Cancer ride, please visit cancerbikeride.org or follow the ride on Instagram , Facebook and LinkedIn by using #C2C4C23.

Infineon Technologies, NXP Semiconductors, and STMicroelectronics Among Major Players in the Growing Global eSIM Market

Retrieved on: 
Thursday, July 20, 2023
Benchmark, NXP Semiconductors, SIM, Smartphone, Valid S.A., Infineon Technologies, India Brand Equity Foundation, Agriculture, COVID-19, ARM, Pew, Sierra Wireless, Human, Ericsson, Tablet, Pew Research Center, Arm (company), Electrospray, Deutsche Telekom, STMicroelectronics, Growth, Telefónica, ESIM, Singtel, Transport, UICC, EUICC, SMS, Mobile phone

This comprehensive report provides critical information for strategists, marketers, and senior management to assess the eSIM market.

Key Points: 
  • This comprehensive report provides critical information for strategists, marketers, and senior management to assess the eSIM market.
  • Assess the direct and indirect effects of the Russia-Ukraine war on agriculture, energy, mineral commodity supply, and the market.
  • Technological advancements are driving the eSIM market, with major companies focusing on expanding the use cases and applications of eSIM offerings.
  • The eSIM market comprises revenues earned by entities providing data-only and voice, SMS, and data services.

Soracom Announces North America's Largest IoT Coverage Area

Retrieved on: 
Tuesday, May 23, 2023
Data Management, Technology, IOT (Internet of Things), Other Technology, Satellite, Telecommunications, Software, Networks, Internet, Mobile, Wireless, Hardware, AT&T, Atmosphere, Soil, Mobile app, Verizon Communications, Entrepreneurship, UICC, Health, T-Mobile, Environment, AWS, Mobile phone, Internet of things

Soracom's new plan, "US-MAX," provides IoT data coverage across the three largest wireless networks in North America: AT&T, T-Mobile, and Verizon.

Key Points: 
  • Soracom's new plan, "US-MAX," provides IoT data coverage across the three largest wireless networks in North America: AT&T, T-Mobile, and Verizon.
  • Soracom's containerized multi-IMSI capability, which is compatible with both eUICC and UICC standards, means that Plan US-MAX is available today as an over-the-air download to any device in North America using Soracom IoT SIMs or eSIMs.
  • Soracom Plan US-MAX gives us the coverage our customers need and the ability to connect securely to our preferred endpoints."
  • Soracom serves as a technology partner to IoT innovators across North America, Europe, and Asia, and we know extensive coverage in specific countries can make or break a deployment," said Kenta Yasukawa, CTO and Co-Founder of Soracom.

Health Equity Report Card Pilot Project to Help Close the Care Gap Highlighted on World Cancer Day

Retrieved on: 
Saturday, February 4, 2023
Union for International Cancer Control, Bias, Insurance, Union, Health equity, Virginia Commonwealth University, Pfizer, Disability, Community engagement, Language, Patient, Genentech, Food, Geography, American Cancer Society Cancer Action Network, MSW, Health, Research, ACS, Built environment, Gender identity, GSK plc, Risk, Failure, UICC, United, American Cancer Society, National Comprehensive Cancer Network, NCCN, AbbVie, Education, HERC, Cancer, Dietary supplement, Nursing, Pharmaceutical industry, Lilly, MD

PLYMOUTH MEETING, Pa., Feb. 4, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers in the United States—joins the call to Close the Care Gap on World Cancer Day, a global awareness day organized by the Union of International Cancer Control (UICC) every February 4, by launching a new Health Equity Report Card (HERC) pilot program. This worldwide message acknowledges the many lives that are lost due to disparities in cancer outcomes. NCCN's work improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives is ongoing around the world. Today's announcement explains more on how the HERC pilot program came about and what it is meant to achieve.

Key Points: 
  • PLYMOUTH MEETING, Pa., Feb. 4, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers in the United States—joins the call to Close the Care Gap on World Cancer Day , a global awareness day organized by the Union of International Cancer Control (UICC) every February 4, by launching a new Health Equity Report Card ( HERC ) pilot program.
  • NCCN's work improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives is ongoing around the world.
  • "Ensuring equity in cancer care is critical to reducing cancer disparities and ending cancer as we know it, for everyone.
  • The Health Equity Report Card provides a tangible approach that can help achieve that goal."

Health Equity Report Card Pilot Project to Help Close the Care Gap Highlighted on World Cancer Day

Retrieved on: 
Saturday, February 4, 2023
Union for International Cancer Control, Bias, Insurance, Union, Health equity, Virginia Commonwealth University, Pfizer, Disability, Community engagement, Language, Patient, Genentech, Food, Geography, American Cancer Society Cancer Action Network, MSW, Health, Research, ACS, Built environment, Gender identity, GSK plc, Risk, Failure, UICC, United, American Cancer Society, National Comprehensive Cancer Network, NCCN, AbbVie, Education, HERC, Cancer, Dietary supplement, Nursing, Pharmaceutical industry, Lilly, MD

PLYMOUTH MEETING, Pa., Feb. 4, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers in the United States—joins the call to Close the Care Gap on World Cancer Day, a global awareness day organized by the Union of International Cancer Control (UICC) every February 4, by launching a new Health Equity Report Card (HERC) pilot program. This worldwide message acknowledges the many lives that are lost due to disparities in cancer outcomes. NCCN's work improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives is ongoing around the world. Today's announcement explains more on how the HERC pilot program came about and what it is meant to achieve.

Key Points: 
  • PLYMOUTH MEETING, Pa., Feb. 4, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading cancer centers in the United States—joins the call to Close the Care Gap on World Cancer Day , a global awareness day organized by the Union of International Cancer Control (UICC) every February 4, by launching a new Health Equity Report Card ( HERC ) pilot program.
  • NCCN's work improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives is ongoing around the world.
  • "Ensuring equity in cancer care is critical to reducing cancer disparities and ending cancer as we know it, for everyone.
  • The Health Equity Report Card provides a tangible approach that can help achieve that goal."

Fujifilm Europe supports World Cancer Day

Retrieved on: 
Monday, January 23, 2023
Disease, Education, Diagnosis, Lead, Cancer, Health, Patient, Capacity building, Partnership, UICC, Algorithm, Union for International Cancer Control, Fujifilm, Union, Pharmaceutical industry, Medical imaging

RATINGEN, Germany, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Fujifilm Europe has announced its partnership with World Cancer Day, an initiative led by the Union for International Cancer Control (UICC), the largest and oldest international cancer organisation dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite the cancer community to reduce the global cancer burden, promote greater equity, and integrate cancer control into the world health and development agenda.

Key Points: 
  • RATINGEN, Germany, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Fujifilm Europe has announced its partnership with World Cancer Day, an initiative led by the Union for International Cancer Control (UICC), the largest and oldest international cancer organisation dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite the cancer community to reduce the global cancer burden, promote greater equity, and integrate cancer control into the world health and development agenda.
  • When it comes to cancer, many people are denied basic care, despite the fact that we live in a time of awe-inspiring advancements in cancer prevention, diagnosis and treatment.
  • Toshihisa Iida, President and Managing Director at FUJIFILM Europe GmbH, commented: “We are extremely proud to be a partner of World Cancer Day, and to show our dedication to advancing the fight against cancer.
  • We have achieved a lot in the last decade in cancer care and control around the world but not addressing inequities in society is slowing our progress.

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory:

The Medicines Patent Pool (MPP) signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

Retrieved on: 
Thursday, October 20, 2022
Selection, Congress, Use, Medicine, Development, UICC, Non-communicable disease, Union, Essential medicines, Novartis, Sustainability, EOI, Patient, Private sector, Research, Access, MPP, Cancer, WHO, EML, Union for International Cancer Control, Nilotinib, World, WHO Model List of Essential Medicines, B cell, WHO Expert Committee on Leprosy, Agency, CML, SDC, Prognosis, Unitaid, Global Health, Coalition, Acute leukemia, Medicines Patent Pool, ATOM, Pharmaceutical industry, Medical imaging, Developing country

GENEVA, Oct. 20, 2022 /PRNewswire/ -- On the side lines of the World Cancer Congress, the Medicines Patent Pool (MPP) today announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least one year of age.

Key Points: 
  • Advances in treatment, such as nilotinib, have contributed to a greatly improved prognosis for people diagnosed with CML.
  • Nilotinib was added to the WHO EML and EMLc respectively in 2017 and 2019 as second-line therapy for the treatment of chronic myeloid leukaemia that is resistant to imatinib.
  • MPP's work on access to NCDs is equally funded by Unitaid and the Swiss Agency for Development and Cooperation (SDC).
  • MPP invites Expressions of Interest (EoI) from potential sublicensees for sublicences to manufacture and sell nilotinib in the licensed territory: